343 related articles for article (PubMed ID: 16793959)
1. Oxidised low-density lipoprotein concentration - early marker of an altered lipid metabolism in young women with PCOS.
Macut D; Damjanovic S; Panidis D; Spanos N; Glisic B; Petakov M; Rousso D; Kourtis A; Bjekic J; Milic N
Eur J Endocrinol; 2006 Jul; 155(1):131-6. PubMed ID: 16793959
[TBL] [Abstract][Full Text] [Related]
2. Lipid and lipoprotein profile in women with polycystic ovary syndrome.
Macut D; Panidis D; Glisić B; Spanos N; Petakov M; Bjekić J; Stanojlović O; Rousso D; Kourtis A; Bozić I; Damjanović S
Can J Physiol Pharmacol; 2008 Apr; 86(4):199-204. PubMed ID: 18418429
[TBL] [Abstract][Full Text] [Related]
3. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
[TBL] [Abstract][Full Text] [Related]
4. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N
Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS.
Zhang J; Fan P; Liu H; Bai H; Wang Y; Zhang F
Hum Reprod; 2012 Aug; 27(8):2484-93. PubMed ID: 22674204
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of endothelial dysfunction, lipid metabolism in women with polycystic ovary syndrome: relationship of paraoxonase 1 activity, malondialdehyde levels, low-density lipoprotein subfractions, and endothelial dysfunction.
Bayram F; Kocer D; Ozsan M; Muhtaroglu S
Gynecol Endocrinol; 2012 Jul; 28(7):497-501. PubMed ID: 22703625
[TBL] [Abstract][Full Text] [Related]
7. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables.
Holte J; Bergh T; Berne C; Lithell H
Clin Endocrinol (Oxf); 1994 Oct; 41(4):463-71. PubMed ID: 7955457
[TBL] [Abstract][Full Text] [Related]
8. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome.
Rajkhowa M; Neary RH; Kumpatla P; Game FL; Jones PW; Obhrai MS; Clayton RN
J Clin Endocrinol Metab; 1997 Oct; 82(10):3389-94. PubMed ID: 9329374
[TBL] [Abstract][Full Text] [Related]
9. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study.
Valkenburg O; Steegers-Theunissen RP; Smedts HP; Dallinga-Thie GM; Fauser BC; Westerveld EH; Laven JS
J Clin Endocrinol Metab; 2008 Feb; 93(2):470-6. PubMed ID: 18056772
[TBL] [Abstract][Full Text] [Related]
10. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters.
Pirwany IR; Fleming R; Greer IA; Packard CJ; Sattar N
Clin Endocrinol (Oxf); 2001 Apr; 54(4):447-53. PubMed ID: 11318779
[TBL] [Abstract][Full Text] [Related]
11. Obesity and inflammatory biomarkers in women with polycystic ovary syndrome.
Shen SH; Shen SY; Liou TH; Hsu MI; Chang YC; Cheng CY; Hsu CS; Tzeng CR
Eur J Obstet Gynecol Reprod Biol; 2015 Sep; 192():66-71. PubMed ID: 26177495
[TBL] [Abstract][Full Text] [Related]
12. Metabolic approaches to the subclassification of polycystic ovary syndrome.
Norman RJ; Masters SC; Hague W; Beng C; Pannall P; Wang JX
Fertil Steril; 1995 Feb; 63(2):329-35. PubMed ID: 7843439
[TBL] [Abstract][Full Text] [Related]
13. Metastin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.
Yilmaz SA; Kerimoglu OS; Pekin AT; Incesu F; Dogan NU; Celik C; Unlu A
Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():56-60. PubMed ID: 25020276
[TBL] [Abstract][Full Text] [Related]
14. Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome.
Glintborg D; Altinok M; Mumm H; Buch K; Ravn P; Andersen M
Hum Reprod; 2014 Aug; 29(8):1773-9. PubMed ID: 24903198
[TBL] [Abstract][Full Text] [Related]
15. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome.
Berneis K; Rizzo M; Lazzarini V; Fruzzetti F; Carmina E
J Clin Endocrinol Metab; 2007 Jan; 92(1):186-9. PubMed ID: 17062762
[TBL] [Abstract][Full Text] [Related]
16. Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome.
Zueff LF; Martins WP; Vieira CS; Ferriani RA
Ultrasound Obstet Gynecol; 2012 Mar; 39(3):341-7. PubMed ID: 21898634
[TBL] [Abstract][Full Text] [Related]
17. Hypoadiponectinemia: a useful marker of dyslipidemia in women with polycystic ovary syndrome.
Chang CY; Chen MJ; Yang WS; Yeh CY; Ho HN; Chen SU; Yang YS
Taiwan J Obstet Gynecol; 2012 Dec; 51(4):583-90. PubMed ID: 23276562
[TBL] [Abstract][Full Text] [Related]
18. Smaller LDL particle size in women with polycystic ovary syndrome compared to controls.
Dejager S; Pichard C; Giral P; Bruckert E; Federspield MC; Beucler I; Turpin G
Clin Endocrinol (Oxf); 2001 Apr; 54(4):455-62. PubMed ID: 11318780
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
20. Glucose-to-insulin ratio rather than sex hormone-binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome.
Ducluzeau PH; Cousin P; Malvoisin E; Bornet H; Vidal H; Laville M; Pugeat M
J Clin Endocrinol Metab; 2003 Aug; 88(8):3626-31. PubMed ID: 12915646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
